-
Neuropsychiatric Disease and Treatment
-
About Dovepress
Open access peer-reviewed scientific and medical journals.
-
Open Access
Dove Medical Press is now a member of the Open Access Initiative
-
An Author's Guide
A guide to help authors get their paper published.
-
Advocacy
Support Open Access and Dove Press
-
Reprints
Promotional Article Monitoring - further details
-
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Update on the use of pramipexole in the treatment of Parkinson’s disease
Review
(2237) Views (527) Full article downloads
Author: Radu Constantinescu
Published Date April 2008
Volume 2008:4(2) Pages 337 - 352
DOI: http://dx.doi.org/10.2147/NDT.S2325
Radu Constantinescu
Department of Neurology, Sahlgrenska University Hospital, 413 45 Göteborg, Sweden
Abstract: Pramipexole is a non-ergot dopamine agonist shown to be efficacious in the treatment of Parkinson’s disease (PD). This review addresses the literature concerning pramipexole’s efficacy in treating motor and non-motor symptoms in PD, its impact on the development of dyskinesias and response fluctuations, the issue of neuroprotection, and the risk for developing adverse events such as increased somnolence, attacks of sudden onset of sleep, cardiac valvulopathy and impulse control disturbances.
Keywords: pramipexole, Parkinson’s disease, efficacy, adverse events
- Have an opinion about one of our articles?
We encourage you to write a Letter to the Editor
- Journal Indexing
See where all the Dove Press journals are indexed
- Testimonials
"... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University
- Long-term treatment of bipolar disorder with a radioelectric asymmetric conveyor
- Implementing the 2009 Institute of Medicine recommendations on resident physician work hours, supervision, and safety
- Topiramate in the prevention and treatment of migraine: efficacy, safety and patient preference
- Moderate alcohol consumption and cognitive risk
